Another group indicated on NSCLC TMA samples that a high number of stromal CD4+ and epithelial and stromal CD8+ cells were independent positive prognostic markers, and CD8+ tumor‐infiltrating lymphocytes (TILs) can stratify immunotherapy‐treated patients of different clinical outcome [43]. This evidence concerns the gene CD8A and neoplasm.